# Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects

> **NCT01068756** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 14 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Rifampin

## Key facts

- **NCT ID:** NCT01068756
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2016-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01068756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01068756, "Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01068756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*